Pharmaceutical Technical Exchange Association Annual Conference
With the uptake of artificial intelligence (AI) in drug discovery and development, Stephanie Pasas-Farmer, PhD, will discuss the current status of AI in drug discovery and development, as well as challenges and regulatory landscape that defines our future and how we implement AI solutions.
What: AI Use in Drug Discovery and Development
When: October 26, 1:30 pm – 2:00 pm CT
Where: PTEA Annual Conference, Overland Park Convention Center, Overland Park, KS
Who: Stephanie Pasas-Farmer, PhD
October 26, 2023
Artificial Intelligence (AI) is increasing efficiencies in drug discovery and development by automating human tasks that are repetitive, demand accuracy and/or require immense resources. Using some case studies, we will highlight the benefits of AI solutions, as well as discuss challenges that the industry faces in the adoption of AI solutions, such as:
- Regulatory: lack of guidance for low-risk AI tools; use of existing approval pathways for high-risk AI solutions without addressing some major issues
- Data: inaccessibility to large amounts of quality training data
- Awareness: limited understanding of AI
- Cognitive biases that shape erroneous and biased models
- Implementation challenges